Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2r)-2-amino-3-phenylpropyl Carbamate
2. (r)-2-amino-3-phenylpropylcarbamate Hydrochloride
3. Adx-n05
4. Benzenepropanol, Beta-amino-, Carbamate (ester), (betar)-
5. Jzp-110
6. Solriamfetol
7. Sunosi
1. Jzp-110 Hydrochloride
2. 178429-65-7
3. Solriamfetol (hydrochloride)
4. K7ro88sp7a
5. Solriamfetol Hydrochloride [usan]
6. Solriamfetol Hydrochloride (usan)
7. R-228060
8. Sunosi (tn)
9. Unii-k7ro88sp7a
10. Adx-n05 Hydrochloride
11. Ykp-10a Hydrochloride
12. Schembl8430382
13. Adx-n-05 Hydrochloride
14. Skl-n-05 Hydrochloride
15. Chembl4297212
16. Dtxsid101027927
17. R-228060 Hydrochloride
18. Hy-109043a
19. Solriamfetol Hydrochloride [mi]
20. Solriamfetol Hydrochloride [who-dd]
21. Cs-0112102
22. O-carbamoyl-(d)-phenylalaninol Hydrochloride
23. D11328
24. Solriamfetol Hydrochloride [orange Book]
25. (d)-o-carbamoylphenylalaninol Hydrochloride Salt
26. R228060;jzp-110;adx-n05;skl-n05;ykp-10
27. (2r)-2-amino-3-phenylpropyl Carbamate, Monohydrochloride
28. (betar)-beta-amino-benzenepropanol 1-carbamate Hydrochloride (1:1)
29. (r)-(+)-2-amino-1-carbamoyloxy-3-phenylpropane Hydrochloride
30. Benzenepropanol, .beta.-amino-, 1-carbamate, Hydrochloride (1:1), (.beta.r)-
31. 561069-23-6
Molecular Weight | 230.69 g/mol |
---|---|
Molecular Formula | C10H15ClN2O2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 230.0822054 g/mol |
Monoisotopic Mass | 230.0822054 g/mol |
Topological Polar Surface Area | 78.3 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 179 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).
Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).
N06BA14
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for major depressive disorder (MDD) with and without severe excessive daytime sleepiness.
Lead Product(s): Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2025
Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Reports PARADIGM Ph 3 Results Of Solriamfetol in MDD wth/without EDS
Details : Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for major depressive disorder (MDD) with and without severe excessive daytime sleepiness.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 01, 2025
Details:
Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for the treatment of attention deficit hyperactivity disorder.
Lead Product(s): Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2025
Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome’s Phase 3 FOCUS Trial of Solriamfetol in ADHD Meets Endpoint
Details : Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for the treatment of attention deficit hyperactivity disorder.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 25, 2025
Details:
Undisclosed
Lead Product(s): Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 17, 2025
Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Safety Study of Solriamfetol in Subjects with Binge Eating Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 17, 2025
Details:
Undisclosed
Lead Product(s): Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area: Sleep Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 23, 2024
Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 23, 2024
Details:
Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy.
Lead Product(s): Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area: Sleep Brand Name: Sunosi
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2024
Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Highlights Data on Solriamfetol Showing Cognitive Improvement in Narcolepsy
Details : Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 29, 2024
Details:
Undisclosed
Lead Product(s): Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2024
Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 14, 2024
Details:
Undisclosed
Lead Product(s): Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 11, 2024
Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 11, 2024
Details:
Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of major depressive disorder.
Lead Product(s): Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2024
Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Initiates PARADIGM Phase 3 Of Solriamfetol For Major Depressive Disorder Treatment
Details : Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of major depressive disorder.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 19, 2024
Details:
Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of binge eating disorder.
Lead Product(s): Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 04, 2024
Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Initiates ENGAGE Phase 3 Trial of Solriamfetol for Binge Eating Disorder
Details : Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of binge eating disorder.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 04, 2024
Details:
Undisclosed
Lead Product(s): Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: National Multiple Sclerosis Society | Axsome Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 14, 2023
Lead Product(s) : Solriamfetol Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : National Multiple Sclerosis Society | Axsome Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 14, 2023
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
37
PharmaCompass offers a list of Solriamfetol Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Solriamfetol Hydrochloride manufacturer or Solriamfetol Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Solriamfetol Hydrochloride manufacturer or Solriamfetol Hydrochloride supplier.
PharmaCompass also assists you with knowing the Solriamfetol Hydrochloride API Price utilized in the formulation of products. Solriamfetol Hydrochloride API Price is not always fixed or binding as the Solriamfetol Hydrochloride Price is obtained through a variety of data sources. The Solriamfetol Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Solriamfetol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Solriamfetol, including repackagers and relabelers. The FDA regulates Solriamfetol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Solriamfetol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Solriamfetol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Solriamfetol supplier is an individual or a company that provides Solriamfetol active pharmaceutical ingredient (API) or Solriamfetol finished formulations upon request. The Solriamfetol suppliers may include Solriamfetol API manufacturers, exporters, distributors and traders.
click here to find a list of Solriamfetol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Solriamfetol DMF (Drug Master File) is a document detailing the whole manufacturing process of Solriamfetol active pharmaceutical ingredient (API) in detail. Different forms of Solriamfetol DMFs exist exist since differing nations have different regulations, such as Solriamfetol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Solriamfetol DMF submitted to regulatory agencies in the US is known as a USDMF. Solriamfetol USDMF includes data on Solriamfetol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Solriamfetol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Solriamfetol suppliers with USDMF on PharmaCompass.
A Solriamfetol written confirmation (Solriamfetol WC) is an official document issued by a regulatory agency to a Solriamfetol manufacturer, verifying that the manufacturing facility of a Solriamfetol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Solriamfetol APIs or Solriamfetol finished pharmaceutical products to another nation, regulatory agencies frequently require a Solriamfetol WC (written confirmation) as part of the regulatory process.
click here to find a list of Solriamfetol suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Solriamfetol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Solriamfetol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Solriamfetol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Solriamfetol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Solriamfetol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Solriamfetol suppliers with NDC on PharmaCompass.
Solriamfetol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Solriamfetol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Solriamfetol GMP manufacturer or Solriamfetol GMP API supplier for your needs.
A Solriamfetol CoA (Certificate of Analysis) is a formal document that attests to Solriamfetol's compliance with Solriamfetol specifications and serves as a tool for batch-level quality control.
Solriamfetol CoA mostly includes findings from lab analyses of a specific batch. For each Solriamfetol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Solriamfetol may be tested according to a variety of international standards, such as European Pharmacopoeia (Solriamfetol EP), Solriamfetol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Solriamfetol USP).